Europe rejects drug to slow Alzheimer's disease due to side effects

The European Medicines Agency has ruled out giving the drug a license. One of the first drugs to try to stop Alzheimer’s disease.. Do LecanemabIt is a drug that was approved last year by the US Food and Drug Administration (FDA), and is marketed under the name Leqembi.

After the US regulatory approval, the European Commission was expected to issue its decision on the drug, and its conclusion was that the European Commission should not grant a license. Drug marketing license.

The European Medicines Agency’s Committee for Medicinal Products for Human Use had indicated that a delay in cognitive impairment had been achieved. It does not compensate for its side effects.Which may be dangerous in some cases, as is the case now. brain swelling or bleeding.

The drug was developed by pharmaceutical companies Eisai and Biogen based on a study of about 1,800 male and female patients. With Catalan participationThe Alzheimer’s Center in Barcelona contributed 20% of the patients.

The drug, which was rejected by the European Medicines Agency, was approved by the US regulatory body last year (Europa Press)

Lights and Shadows of Clinical Trial

Experiments have shown that the drug Slows the progression of Alzheimer’s disease in 27% of patients And it can get about 4 or 5 months of life if you take it for more than a year and a half. Specifically, what the drug does is reduce amyloid plaques, which are toxic to the brain.

However, some patients had side effects and Two participants in the experiment died, Possibly due to the effects of Lecanemab in people with circulation problems.

In fact, the FDA recommends against prescribing the drug to patients taking anticoagulant medications, due to the risk of inflammation and bleeding in the brain, and stresses that it should be used in people with mild cognitive impairment and in the early stages of the disease.

One in 10 people over the age of 65 will develop Alzheimer’s disease.According to the Pascual Maragall Foundation, this disease has no cure and causes loss of memory and memories, and over time, those affected are not aware of the reality around them.